Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson

 
• By Cathy Kelly
  
CMS' Approach To Valuing Drugs Remains To Be Seen • Source: Shutterstock

More from Market Access

More from Pink Sheet